Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state
- 8 February 2011
- journal article
- review article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 52 (sup1), 23-29
- https://doi.org/10.3109/10428194.2010.546912
Abstract
BCR–ABL1 kinase-induced chronic myeloid leukemia in chronic phase (CML-CP) usually responds to treatment with ABL tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib. In most patients TKIs reduce the leukemia cell load substantially, but some leukemia cells, for example leukemia stem cells (LSCs), are intrinsically refractory to TKIs. In addition, some patients who respond initially may later become resistant to TKIs due to accumulation of point mutations in BCR–ABL1 kinase. LSCs or their progeny, leukemia progenitor cells (LPCs), at some stage may acquire additional genetic changes that cause the leukemia to transform further to a more advanced blast phase (CML-BP), which responds poorly to treatment and is usually fatal. We postulate that LSCs and/or LPCs refractory or resistant to TKIs may be ‘ticking time-bombs’ accumulating additional genetic aberrations and eventually ‘exploding’ to generate additional TKI-resistant clones and CML-BP clones with complex karyotypes.Keywords
This publication has 79 references indexed in Scilit:
- BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repairBlood, 2009
- Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic CellsCancer Research, 2008
- BCR/ABL and Other Kinases from Chronic Myeloproliferative Disorders Stimulate Single-Strand Annealing, an Unfaithful DNA Double-Strand Break RepairCancer Research, 2008
- BCR/ABL Inhibits Mismatch Repair to Protect from Apoptosis and Induce Point MutationsCancer Research, 2008
- Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyJCI Insight, 2007
- Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatmentProceedings of the National Academy of Sciences of the United States of America, 2007
- Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutantsProceedings of the National Academy of Sciences of the United States of America, 2006
- Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to ImatinibMolecular and Cellular Biology, 2006
- Loss of p53 impedes the antileukemic response to BCR-ABL inhibitionProceedings of the National Academy of Sciences of the United States of America, 2006
- Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemiaProceedings of the National Academy of Sciences of the United States of America, 2006